$Moderna, Inc.(MRNA)$ $Pfizer(PFE)$ $SELLAS Life Sciences Group Inc.(SLS)$ $Johnson & Johnson(JNJ)$
Breaking news here. Hopefully some of you bought the dip last week.
Big breakout expected next week, starting Monday. Mark this post.
Major data came out Saturday, October 24. Honestly, I'm surprised investors aren't talking about it yet.
This is a big deal.
$AbCellera Biologics(ABCL)$ — new Phase 3 data for T-cell engagers.
Amgen just released detailed results from its Phase 3 DeLLphi-305 trial at ESMO 2026, and the numbers are impressive.
58% reduction in the risk of death.
Median overall survival: 21.1 months vs. 12.7 months.
One-year survival: 79% vs. 53%.
Progression-free survival: 7.4 months vs. 1.9 months.
This is a T-cell engager treating one of the most aggressive forms of lung cancer.
The trial's success was announced in September, but these detailed survival numbers were released October 24.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
